Harish Dave

Aum Biosciences Ltd. is a global clinical-stage oncology. It is focused on advancing a pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance. The company was founded on October 28, 2022 and is headquartered in George Town, Cayman Islands.

Part of AUM Biosciences Ltd., AUM Biosciences Pte Ltd. is a clinical-stage biotech company based in Singapore, Singapore. The Singaporean company focuses on discovering and developing novel targeted oncology therapies, particularly for cancers with a clear genetic marker. AUM Biosciences has an extensive track record of selecting distinctive early-stage assets, successfully exiting virtual biotech models, and contributing significantly to the development of several currently marketed oncology treatments with annual peak sales up to $3 billion. AUM Biosciences is advancing a broad portfolio of precision oncology therapeutics, including AUM001, AUM601, and AUM302, which have entered clinical trials and received orphan drug designation from the FDA for the treatment of various cancers. The company was founded by Harish Dave and is currently led by CEO Vishal Doshi.

Aum Biosciences Ltd. is a global clinical-stage oncology. It is focused on advancing a pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance. The company was founded on October 28, 2022 and is headquartered in George Town, Cayman Islands.

Part of AUM Biosciences Ltd., AUM Biosciences Pte Ltd. is a clinical-stage biotech company based in Singapore, Singapore. The Singaporean company focuses on discovering and developing novel targeted oncology therapies, particularly for cancers with a clear genetic marker. AUM Biosciences has an extensive track record of selecting distinctive early-stage assets, successfully exiting virtual biotech models, and contributing significantly to the development of several currently marketed oncology treatments with annual peak sales up to $3 billion. AUM Biosciences is advancing a broad portfolio of precision oncology therapeutics, including AUM001, AUM601, and AUM302, which have entered clinical trials and received orphan drug designation from the FDA for the treatment of various cancers. The company was founded by Harish Dave and is currently led by CEO Vishal Doshi.

Aum Biosciences Ltd. is a global clinical-stage oncology. It is focused on advancing a pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance. The company was founded on October 28, 2022 and is headquartered in George Town, Cayman Islands.

Part of AUM Biosciences Ltd., AUM Biosciences Pte Ltd. is a clinical-stage biotech company based in Singapore, Singapore. The Singaporean company focuses on discovering and developing novel targeted oncology therapies, particularly for cancers with a clear genetic marker. AUM Biosciences has an extensive track record of selecting distinctive early-stage assets, successfully exiting virtual biotech models, and contributing significantly to the development of several currently marketed oncology treatments with annual peak sales up to $3 billion. AUM Biosciences is advancing a broad portfolio of precision oncology therapeutics, including AUM001, AUM601, and AUM302, which have entered clinical trials and received orphan drug designation from the FDA for the treatment of various cancers. The company was founded by Harish Dave and is currently led by CEO Vishal Doshi.

Aum Biosciences Ltd. is a global clinical-stage oncology. It is focused on advancing a pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance. The company was founded on October 28, 2022 and is headquartered in George Town, Cayman Islands.

Part of AUM Biosciences Ltd., AUM Biosciences Pte Ltd. is a clinical-stage biotech company based in Singapore, Singapore. The Singaporean company focuses on discovering and developing novel targeted oncology therapies, particularly for cancers with a clear genetic marker. AUM Biosciences has an extensive track record of selecting distinctive early-stage assets, successfully exiting virtual biotech models, and contributing significantly to the development of several currently marketed oncology treatments with annual peak sales up to $3 billion. AUM Biosciences is advancing a broad portfolio of precision oncology therapeutics, including AUM001, AUM601, and AUM302, which have entered clinical trials and received orphan drug designation from the FDA for the treatment of various cancers. The company was founded by Harish Dave and is currently led by CEO Vishal Doshi.

Aum Biosciences Ltd. is a global clinical-stage oncology. It is focused on advancing a pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance. The company was founded on October 28, 2022 and is headquartered in George Town, Cayman Islands.

Part of AUM Biosciences Ltd., AUM Biosciences Pte Ltd. is a clinical-stage biotech company based in Singapore, Singapore. The Singaporean company focuses on discovering and developing novel targeted oncology therapies, particularly for cancers with a clear genetic marker. AUM Biosciences has an extensive track record of selecting distinctive early-stage assets, successfully exiting virtual biotech models, and contributing significantly to the development of several currently marketed oncology treatments with annual peak sales up to $3 billion. AUM Biosciences is advancing a broad portfolio of precision oncology therapeutics, including AUM001, AUM601, and AUM302, which have entered clinical trials and received orphan drug designation from the FDA for the treatment of various cancers. The company was founded by Harish Dave and is currently led by CEO Vishal Doshi.